These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27143132)

  • 41. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
    Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
    Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
    Carbajo-García MC; García-Alcázar Z; Corachán A; Monleón J; Trelis A; Faus A; Pellicer A; Ferrero H
    Fertil Steril; 2022 Feb; 117(2):433-443. PubMed ID: 34809976
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
    Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
    Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
    J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
    Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
    Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.
    Ling Y; Wang X; Wang C; Xu C; Zhang W; Zhang Y; Zhang Y
    ChemMedChem; 2015 Jun; 10(6):971-6. PubMed ID: 25882299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas.
    Lee J; Ko J; Yi JY
    J Dermatol Sci; 2018 Apr; 90(1):13-20. PubMed ID: 29290529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Syntheses and Biological Evaluation of Novel Hydroxamic Acid Derivatives Containing Purine Moiety as Histone Deacetylase Inhibitors.
    Xu Z; Yang Y; Mai X; Liu B; Xiong Y; Feng L; Liao Y; Zhang Y; Wang H; Ouyang L; Liu S
    Chem Pharm Bull (Tokyo); 2018; 66(4):439-451. PubMed ID: 29607910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.
    Zhu Z; Jiang W; McGinley JN; Thompson HJ
    Cancer Prev Res (Phila); 2013 Apr; 6(4):290-8. PubMed ID: 23365133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
    Canzoneri JC; Chen PC; Oyelere AK
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6588-90. PubMed ID: 19854643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
    Cheng HT; Hung WC
    Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
    Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
    Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
    Gu W; Nusinzon I; Smith RD; Horvath CM; Silverman RB
    Bioorg Med Chem; 2006 May; 14(10):3320-9. PubMed ID: 16434199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Dung DTM; Anh VT; Hue VTM; Han SB; Nam NH
    Bioorg Chem; 2020 Aug; 101():103988. PubMed ID: 32534346
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
    Ling Y; Xu C; Luo L; Cao J; Feng J; Xue Y; Zhu Q; Ju C; Li F; Zhang Y; Zhang Y; Ling X
    J Med Chem; 2015 Dec; 58(23):9214-27. PubMed ID: 26555243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
    Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
    Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.